Early PSA Levels After Prostate Surgery and Cancer Outcomes
Studies whether early PSA blood levels after prostate removal predict later cancer outcomes in adults.
Plain-language title generated from the registry record
Registry title: Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
Key facts
- Where
- Kaunas, LithuaniaSee the site
Where in Lithuania
- Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of UrologyKaunas, LithuaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lithuanian University of Health Sciences
- Trial code
- NCT07516886
- Record updated
- 8 April 2026
- Original description
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.Read full original descriptionShow less
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.
No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.
Inclusion: Patient is an adult biological male; Patient has morphologically confirmed and untreated prostate cancer; Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy; Patient is informed about this observational study and has signed the informed consent form.
Exclusion: Patient received neoadjuvant prostate cancer treatment; Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation; Patient is set to receive adjuvant treatment; Patient has any contraindications for the operation.